D-Index & Metrics Best Publications

Jorma Isola

Tampere University
Finland

Medicine

Finland

2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 101 Citations 37,802 316 World Ranking 4733 National Ranking 55

Research.com Recognitions

Awards & Achievements

2023 - Research.com Medicine in Finland Leader Award

Overview

What is he best known for?

The fields of study Jorma Isola is best known for:

Cancer
Chemotherapy
Gene

His study on Internal medicine is mostly dedicated to connecting different topics, such as Odds ratio. He conducted interdisciplinary study in his works that combined Cancer and Mammography. He performs multidisciplinary study in Mammography and Breast cancer in his work. In his research, he performs multidisciplinary study on Breast cancer and Tamoxifen. He incorporates Tamoxifen and Estrogen in his research. He combines Estrogen and Progesterone receptor in his research. His study deals with a combination of Oncology and Cancer research. Jorma Isola combines Cancer research and Cancer in his research. By researching both Pathology and Immunohistochemistry, Jorma Isola produces research that crosses academic boundaries.

His most cited work include:

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab (605 citations)
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. (321 citations)
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. (293 citations)

What are the main themes of his work throughout his whole career to date

The In situ hybridization portion of his research involves studies in Chromogenic in situ hybridization and CISH. His research on Internal medicine frequently links to adjacent areas such as Estrogen. In his works, he undertakes multidisciplinary study on Estrogen and Breast cancer. He integrates many fields, such as Breast cancer and Cancer research, in his works. He integrates many fields in his works, including Cancer research and Oncology. In his papers, Jorma Isola integrates diverse fields, such as Oncology and Gynecology. Jorma Isola conducts interdisciplinary study in the fields of Gynecology and Internal medicine through his works. His Cancer study frequently draws connections between related disciplines such as Mammary gland. In his study, he carries out multidisciplinary Pathology and Endocrinology research.

Jorma Isola most often published in these fields:

Internal medicine (72.09%)
Cancer (72.09%)
Breast cancer (55.81%)

What were the highlights of his more recent work (between 2008-2016)?

Cancer (75.00%)
Internal medicine (75.00%)
Biochemistry (50.00%)

In recent works Jorma Isola was focusing on the following fields of study:

Jorma Isola undertakes multidisciplinary investigations into Cancer and Cancer research in his work. He merges Cancer research with Cancer in his study. He combines Internal medicine and Oncology in his research. He integrates Oncology with Internal medicine in his study. In most of his Biochemistry studies, his work intersects topics such as Polymerase. Jorma Isola performs multidisciplinary studies into Polymerase and Enzyme in his work. Enzyme and Biochemistry are two areas of study in which Jorma Isola engages in interdisciplinary work. Jorma Isola regularly links together related areas like Hormone therapy in his Breast cancer studies. His research on Hormone therapy often connects related topics like Breast cancer.

Between 2008 and 2016, his most popular works were:

Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland (46 citations)
Very high quantitative tumor HER2 content and outcome in early breast cancer (21 citations)
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry (13 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Tapio Visakorpi;Eija Hyytinen;Pasi Koivisto;Minna Tanner.
Nature Genetics (1995)

1820 Citations

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Heikki Joensuu;Pirkko-Liisa Kellokumpu-Lehtinen;Petri Bono;Tuomo Alanko.
The New England Journal of Medicine (2006)

1798 Citations

Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.

Olli‐P ‐P Kallioniemi;Anne Kallioniemi;Jim Piper;Jorma Isola.
Genes, Chromosomes and Cancer (1994)

1215 Citations

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

Ari Ristimäki;Anna Sivula;Johan Lundin;Mikael Lundin.
Cancer Research (2002)

1144 Citations

Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer

Pasi Koivisto;Juha Kononen;Christian Palmberg;Teuvo Tammela.
Cancer Research (1997)

943 Citations

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

M. Tanner;M. Hollmén;T. T. Junttila;A. I. Kapanen.
Annals of Oncology (2005)

870 Citations

Inherited susceptibility to uterine leiomyomas and renal cell cancer

Virpi Launonen;Outi Vierimaa;Maija Ht Kiuru;Jorma Isola.
Proceedings of the National Academy of Sciences of the United States of America (2001)

708 Citations

Genetic Changes in Primary and Recurrent Prostate Cancer by Comparative Genomic Hybridization

Tapio Visakorpi;Anne H. Kallioniemi;Ann-Christine Syvänen;Eija R. Hyytinen.
Cancer Research (1995)

636 Citations

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

Lao H. Saal;Peter Johansson;Karolina Holm;Sofia K. Gruvberger-Saal.
Proceedings of the National Academy of Sciences of the United States of America (2007)

608 Citations

Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line

Peter Nagy;Elza Friedländer;Minna Tanner;Anita I. Kapanen.
Cancer Research (2005)

593 Citations

If you think any of the details on this page are incorrect, let us know.